David A. Siegel Harmony Biosciences Holdings, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 140,800 shares of HRMY stock, worth $5.04 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
140,800
Previous 98,900
42.37%
Holding current value
$5.04 Million
Previous $3.4 Million
37.32%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding HRMY
# of Institutions
281Shares Held
44.8MCall Options Held
130KPut Options Held
46.5K-
Valor Management LLC Chicago, IL6.62MShares$237 Million91.68% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$209 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.7MShares$168 Million0.0% of portfolio
-
State Street Corp Boston, MA1.58MShares$56.5 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO1.29MShares$46.1 Million0.03% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.12B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...